Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Rapport Therapeutics, Inc.’s reported figures.
The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333862
FAQ
- What is Rapport Therapeutics, Inc.'s EBIT?
- Rapport Therapeutics, Inc. (RAPP) reported EBIT of -$60.81M in Q2 2026.
- How has Rapport Therapeutics, Inc.'s EBIT changed year-over-year?
- Rapport Therapeutics, Inc.'s EBIT decreased by 106.1% year-over-year, from -$29.5M to -$60.81M.
- What is the long-term trend for Rapport Therapeutics, Inc.'s EBIT?
- Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s EBIT has grown at a 86.0% compound annual growth rate (CAGR), from -$36.18M to -$125.1M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Rapport Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude